ReviewNanomaterials (Basel, Switzerland)2024
Nanocarrier-Based Eco-Friendly RNA Pesticides for Sustainable Management of Plant Pathogens and Pests.
Review in Nanomaterials (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cross-kingdom RNA in plant-microbe interactions: from molecular interactions to next-generation crop protection.Stress biology · 2026Review
- Nano-enabled spray-induced RNA interference against fungal pathogens of oilseed crops: carrier performance, delivery evidence and field translation.World journal of microbiology & biotechnology · 2026Review
- Nanoparticle-Mediated RNAi Delivery System Targeting theInsects · 2026Article
- Functional Analysis of Adipokinetic Hormone and Its Receptor Genes in Regulating Energy Metabolism Under Stress Conditions inInternational journal of molecular sciences · 2026Article
- Antimicrobial resistance in plant-associated microbial communities: mechanisms, ecology, and one health implications.Frontiers in microbiology · 2026Review
- Fungal-derived ZnO nanoparticles functionalized with riboflavin and UDP-GlcNAc exhibit potent nematicidal activity against M. incognita.Scientific reports · 2025Article
- Nanoparticles and Nanocarriers for Managing Plant Viral Diseases.Plants (Basel, Switzerland) · 2025Review
- Managing African Armyworm Outbreaks in Sub-Saharan Africa: Current Strategies and Future Directions.Insects · 2025Review
- Integrating RNA Interference and Nanotechnology: A Transformative Approach in Plant Protection.Plants (Basel, Switzerland) · 2025Review
- The CYP303A1 is essential in embryonic development ofFrontiers in physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The production of healthy agricultural products has increased the demand for innovative and sustainable plant protection technologies. RNA interference (RNAi), described as post-transcriptional gene silencing, offers great opportunities for developing RNA pesticides for sustainable disease and pest control. Compared with traditional synthesized pesticides, RNA pesticides possess many advantages, such as strong targeting, good environmental compatibility, and an easy development process. In this review, we systematically introduce the development of RNAi technology, highlight the advantages of RNA pesticides, and illustrate the challenges faced in developing high-efficiency RNA pesticides and the benefits of nanocarriers. Furthermore, we introduce the process and mechanism of nanocarrier-mediated RNAi technology, summarize the applications of RNA pesticides in controlling plant pathogens and pests, and finally outline the current challenges and future prospects. The current review provides theoretical guidance for the in-depth research and diversified development of RNA pesticides, which can promote the development and practice of nanocarrier-mediated RNAi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.